The online price of the same anti-cancer drug differs by 15,500 consumers, it is difficult for consumers to distinguish the authenticity-News-Tianya Medicine
2022-06-24: [Article Link] The same bottle of anti-cancer Sycorret is available online at prices ranging from 53,000 to 37,500.
Why the difference between the price of the same anti-cancer medicine and 15,500?
The same bottle of Secret, the newly adjusted online price for the Beijing City Drug Purchase Platform is 51,300 Yuan per bottle; the Pfizer China Network Advisory Line offers 53,000 Yuan per bottle; and some online pharmacies offer 37,500 Yuan per bottle, with a price gap of 15,500 Yuan. According to Pfizer, the official Pfizer does not currently publish the price information on the Internet and advises patients not to go to the Internet to buy Sécoré, 'as it is not possible to determine the authenticity of the information. Similarly, 250 g*60 bottles of Sekhari, the newly adjusted online price for the Beijing City Drug Purchase Platform was 51,300 Yuan per bottle; the Pfizer China Network Advisory Line quoted 53,000 Yuan per bottle; and some online pharmacies offered 37,500 Yuan per bottle, with a price gap as high as 15,500 Yuan. According to other intermediaries, patients’ families could be taken to India to buy some 16,000 Yuan bottles of medicine, a different price gap that made the search for drugs impossible. However, cancer patients can be encouraged by the fact that the State is taking a number of measures, such as lowering tariffs on imported medicines, collating water in tender procurement, incorporating health insurance catalogues and promoting the evaluation of the consistency of generic medicines, to reduce the cost of anti-cancer drugs and to reduce their economic burden as soon as possible. Status
The price of the anti-cancer Cycorree's online is not real.
Mr. Yuan's old father was recently diagnosed as a transient non-small cell lung cancer with transgenic lymphoma hormone enzyme (ALK) positive, the name of which appears to be somewhat long and is actually a lung cancer. Doctors recommend a drug, commonly known as Coronerini, and a commodity called Secorre. But the high price surprised Mr. Yuan with a cold sweat: a bottle of 60 capsules and a price of 53,000 Yuan, which is just a monthly dose, and the old father takes two pills a day, which is 1783 Yuan. Although Mr. Yuan is an executive of foreign companies with a diversity of income of 40,000 a month, he is also suffocated by a bottle of anti-cancer medicine of 53,000 Yuan a month, 'even if I don't eat or drink, I have to pay the mortgage and raise the children. "Hearing from the doctor that Sécorre had a charity project for free medicine, I studied it carefully and found that the project was intended to help needy patients, and I'm afraid my family is not in good condition. As a result, Mr. Yuan went to the Internet to look for cheap anti-cancer procurement, but found that the Internet’s wide-ranging distribution of drugs was confusing and inexplicable. There were 45,000 Yuan bottles, 37,500 Yuan bottles, and the agency claimed that it could take him to India to buy a similar Sekori, 16,000 Yuan bottle. Investigations
There's a drugstore, and the price is 70% off.
The Beijing youth newspaper reporter searched the Internet for the word “Secorre” and immediately posted a series of related drug advertisements, all of which were retail quotations for Sécorre. A little bit by one, it turns out that all the main pharmacies have web pages, of which 250 g*60 grains of the Condolence Pharmacy are sold at a price of 52900 Yuan bottles. The therapist in charge of consulting said: 'We buy most of our products directly from the manufacturer, while we compress operating costs with excellent management and maximize the benefits to consumers. There is also a more attractive version of Cycorree’s promotion. The Big Miscreet House in Beijing is launching a Cycorre marketing campaign, with a bottle of 250 g*60 pieces of Cycorre, with a retail price of 37,500 Yuan, which is equivalent to 70% of sales and postage. 'You can choose to buy it at the store. Our pharmacy is on its way to Energetic Economic Development. You can also choose the mail order. We'll pack the mail. According to Pfizer clients, Pfizer’s official office does not currently publish the price of the drug online. She advised patients not to go to the Internet to buy Sycorre’s, because it is not possible to determine whether it is true or not. ' According to this client, there are currently 301 hospitals in Beijing that can be bought in Saikori, the Oncology Hospital of the Chinese Academy of Medical Sciences and 316 hospitals, which were the top three sales in the last quarter. In addition, three regional pharmacies in the Beijing area, namely the Beijing Ka-yung Pharmacy, the North Eun-zi Pharmacy, and the Beijing crane year Pharmacy, were recommended for sale by the Beijing region. Follow-up
It's a high price that drives me to a drug-buying agency.
The high price differential in anti-cancer medicines has prompted a drug-buying agency to go to India. On the Internet, a health-care company was retrieved by a newspaper reporter from the Young People’s North newspaper, who claimed that their Sekhari was a high Indian imitation drug, sold at a price of 16,000 Yuan per bottle, which was 37,000 Yuan less than the domestic price. The company's sales call was consulted by the North Ying newspaper journalist, who stated that they did not sell Indian anti-cancer drugs, but that' we took you to a pharmacy or a hospital in India to buy them, so rest assured that they were bought for the real ones. ' It is understood that the duration of the journey to buy medicines takes three days and two nights and that the costs of air tickets, food and accommodation are borne by the purchasers themselves. From 31 July to 2 August, Beijing's round-trip ticket to Delhi Airport, India, was quoted as 3320 Yuan, two nights' accommodation at the local hotel as 1637 Yuan, and the free bank as 4957 Yuan. This means that 357,000 Yuan would have been less expensive if Mr. Yuan had gone to India to buy 10 bottles of sycore. But Mr. Yuan’s biggest concern is that, after all, pharmaceuticals do not make shoes to make clothes, just like a 89% image. 'As a lot of people in the bar have warned him to go to India to buy drugs at a cheap price, but be very careful, because the unpredictable 'consumption trap' is too much! Analysis
Why is there a huge difference between hospital and pharmacy prices?
In the interview, all the consulting pharmacies claimed that they had imported the drug directly from the factory to prove that it was true. But Pfizer innomers said that Pfizer was selling the drug via a network of first-level agents, and hospitals and pharmacies were buying the drug through a first-level agent. This is analysed by practitioners because the procurement channels for hospitals and pharmacies are quite different. In the past, the flow of medicines has been fixed by a three-tier distribution process, where medicines are produced at all levels of wholesalers and then at the end of the radiation terminal dispensaries, clinics and hospitals. After being sold to patients at a price increase, the prices are too high to be considered socially ill. Subsequently, local health-care authorities introduced a bidding system for the purchase of medicines in public hospitals in order to cut the price of medicines in hospitals, and which drug factory used them at a reasonable price. Starting in January 2017, the State Council's Medical Reform Office introduced a two-barrel system in public hospitals throughout the country, which further reduced the flow of medicines. The "two-barrel system" refers to the issuance of one invoice each from a drug-producing company to a circulating company, a circulating company to a hospital, and the introduction of this programme is aimed at reducing the current multi-level distribution of drugs, so as to avoid the inflated cost of drugs due to the increase in the price of the circulation chain layer. According to the information received, the `two-vote system' has contributed to flatening the flow of medicines, making the route of the flow of drugs and the intermediate price transparent and retroactive, and the State's goal is to reduce the number of enterprises currently in circulation to around 3,000. According to the information received, the “one vote” system is currently being tested in a number of provinces, i.e. the direct settlement of the purchase price by hospitals and pharmaceutical production enterprises, the self-initiation or commissioning of pharmaceutical production enterprises and the issuance of an invoice by pharmaceutical production enterprises to a medical institution. The introduction of the future "one vote" would mean that there might be no change in ownership of medicines and medical devices, and that the circulating company might not have to advance any more money, and that it would be better to be a courier. In the case of high-priced imports of anti-cancer medicines, it is known that the State is taking a number of measures, such as lowering tariffs on imported medicines, flooding the procurement chain in tenders, incorporating health insurance catalogues and promoting the evaluation of the consistency of generic medicines, to reduce the price of anti-cancer drugs and to reduce their economic burden as soon as possible.
It's "innovation" to import anti-cancer drugs to say goodbye.
'Improving our research and development capacity for anti-cancer medicines is fundamental to reducing the cost of anti-cancer medicines and reducing dependence on imported anti-cancer medicines.' The Deputy Director of the National Health Council added.
Launching a world map of the original pharmaceutical industry, the headquarters of the multinational pharmaceutical industry are concentrated in the countries of Europe and America that we know well. Behind a well-known name is often accompanied by expensive prices.
According to the latest data published by the National Cancer Centre, the number of new malignant tumours in the country in 2014 was approximately 384,000 and 2296,000 deaths.
"In the face of such a large group of patients, importing anti-cancer medicines is certainly not enough, and it is necessary to develop its own innovative capacity and innovative medicine to meet the needs of the population.’ The Deputy Director of the National Cancer Center and Vice-President of the Oncology Hospital of the Chinese Academy of Medical Sciences said.
Over the past decade or so, global research and development on anti-cancer medicines has been on the fast track, and new anti-cancer medicines developed in countries and regions such as Europe and America and Japan are on the market. According to the China Medical Industry Information Centre, more than 90% of the more than 4,000 pharmaceutical companies in the country are now generic manufacturers.
'The pharmaceutical industry is built on the original power of innovation.' Says Ishi Wankay.
After the 13th Five-Year Plan, a series of policies to encourage innovation in drug research and development have followed, China has made firm strides in innovative drug research and development, and national research and development of new anti-cancer medicines has become increasingly enthusiastic. In China, small molecules such as Sun Yin and Ishi Wankay, who are involved in research and development, produce innovative drugs to countries such as the anti-cancer drug Ekdenny, giving patients a sense of well-being, and making the government `better' in negotiating the price of the same drug with foreign pharmaceutical companies. The struggle between humans and neoplasms will continue, and Chinese medical innovation is still a long way off, requiring more innovative teams to fight together. 'How do we fight against disease? 'Cause of love and commitment to scientific research, and the duty and responsibility of the healers.' Says Ishi Wanqi.
The authorities put down the price of the anti-cancer medicine.
Every year, more than 14,000,000 new cancer cases occur worldwide, with 380,000 new cancer cases in China in 2014. As the incidence of cancer rises each year, patients are eager to use new drugs, but an expensive anti-cancer medicine is almost unaffordable. Zero tariffs on anti-cancer medicines, negotiations on health insurance, and accelerated approval of new medicines... In order for the population to have easy access to anti-cancer drugs, the relevant State authorities have launched a combination of `priced daily drugs' reduced prices. The price of anti-cancer medicines has been reduced in several provinces.
In recent days, several provincial drug-mining platforms have been issuing information on declining prices for anti-cancer medicines. On 29 June, the public hospital in Hubei province's drug supply guarantee platform issued an announcement stating that, in response to the national tax reform policy, Pfizer's prices for 15 varieties and 20 prescription drugs were reduced by 3.4 - 10.2 per cent on the basis of business applications. These include a decrease of 5.8 per cent in vessel injection for breast cancer; a decrease of 3.8 per cent in the treatment of kidney cancer; a decrease of 3.9 per cent in the treatment of the Secorre capsule for non-small cell lung cancer; and a decrease of 10.2 per cent in the treatment of late intestinal cancer. On 3 July, the price of 50 mg/boxes for the treatment of leukaemia produced by Xi An Youngsen fell from 10327.22 Yuan to 4996 Yuan, a drop of 51.6 per cent.
On 4 July, the Beijing Medical Central Procurement Service issued a reminder that companies such as Pfizer and Cyan Youngsen had purchased autonomous price reductions through the city of Beijing, which included anti-cancer drugs. Of these, the original network price of 250 g*60 was 53,400 Yuan, each of which would be reduced by 2078 Yuan, or 3.9 per cent. On 20 July, the Sanxi Provincial Commission issued a circular on refilling online prices for anti-cancer medicines and imported medicines, and it is expected that by the end of August patients will be able to purchase low-cost anti-cancer medicines at the Sanxi provincial public hospital.
Some provinces and municipalities included exclusive anti-cancer medicines in health care
Some provinces and cities are known to have included Pfizerkori in health care, including Zhejiang, Chengdu, Suzhou, Qingdao, Fuoshan, and Inner Mongolia.
It is known that negotiations on access to health care for exclusive anti-cancer medicines outside the health-care catalogue are under way and that, on 12 July, the National Institute of Health Care indicated that provincially focused procurement of anti-cancer medicines would be carried out. To date, several provinces and municipalities, such as Hubei, Gansu, Beijing, Sichuan, and Shandong, have begun to adjust the price of anti-cancer medicines. 82 of the 103 anti-cancer formulations previously published by the Ministry of Finance have been included in the health-care catalogue (version 2017) and 36 negotiated varieties, which will also be the focus of intensive procurement of anti-cancer medicines. Of the remaining 21 non-health insurance varieties, 17 are exclusive, of which 13 are foreign and 4 are national, which may be the focus of the current access negotiations. In 2017, negotiations on access to the health-care catalogue led to the inclusion in the health-care catalogue of 15 precise but more expensive cancer treatment drugs, such as Hessettine, Merowa and Manko. This year, more than 40 types of medicines have been communicated and negotiated with the National Health Insurance Agency, including Teresa in Asli.
The circular on centralized provincial procurement of anti-cancer medicines (for comments) shows that the State has made specific requests to the provinces, autonomous regions, municipalities directly under the Central Government and the Xinjiang Construction Corps for Medical Protection, the Health Planners (Health and Health) Board and the Human Resources Social Security Department. The circular states that, in follow-up to the State Council's decision to reduce the price of special anti-cancer medicines, to guarantee the clinical needs of cancer patients, to effectively reduce the cost burden on cancer patients, and to achieve a significant reduction in the price of end-use anti-cancer medicines based on the State tax reduction on anti-cancer medicines. It has been decided that a centralized provincial procurement of anti-cancer medicines will be carried out throughout the country, with a clear timetable of tasks: by August 2018, provinces will have introduced a centralized provincial procurement programme for anti-cancer medicines; by September 2018, special procurement will have been fully launched; and by the end of 2018, specialized centralized procurement will have been completed, with full access to the Internet, procurement, clinical use and terminal prices, to the benefit of patients. Advancing the evaluation of generic consistency
A bill for the treatment of haemorrhagic Imaloni sulfonic acid with a specific 0.1 g/60 and a national generic pharmaceutical price of 794.48 Yuan, while imported Imaloni sulfonic acid — Greiver — even if the price has been reduced — currently has the lowest retail price of 6649.96 Yuan, with a price difference of 8.3 times. However, the biggest problem with home-grown generics is how to guarantee product quality and efficacy, and in order to address this problem and improve the quality of home-grown generics, a consistent national evaluation has been carried out. It is understood that generic consistency evaluation refers to a phased assessment of the quality consistency of approved generics, based on the principle of conformity with the quality and efficacy of the original drugs, that is, the need for generics to reach levels of quality and efficacy consistent with the original drugs. On the morning of 26 July, the fifth release of the list of harmonized evaluation varieties was published by the Network of Officials of the National Drug Control Service, which was also the last series of circulars issued by the National Drug Monitoring Service through the harmonized evaluation of the species. According to experts from the pharmaceutical industry, the consistency assessment was a major shuffling of the country's more than 4,000 generic pharmaceutical companies, which in the future will result in the withdrawal of 60 per cent of our generics from the market. According to industry, the impact of brands on prescriptions will be weakened through a consistency assessment, and patients’ sensitivity to the self-payment component will be the main selection factor. At the hospital level, with the introduction of patient-based payments, drugs will become cost-effective in the context of the ratio of medicines to total cost control, and hospitals will be more willing to use low-priced home-grown generics for the same quality. In the form of procurement, most provinces use direct online purchases. In price determination, the provincial attitude is essentially ‘limits’, with Shanghai setting a call to bid for larger or higher-priced varieties; Shanxi, Jiangsu, no higher than the other provinces; Zhejiang, no higher than the online purchase and winning bid in the provinces after a consistent evaluation.